Literature DB >> 7306982

Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.

A Floridi, M G Paggi, S D'Atri, C De Martino, M L Marcante, B Silvestrini, A Caputo.   

Abstract

The action of Lonidamine [1-(2,4-dichlorobenzyl)-1-H-indazol-3-carboxylic acid] on oxygen consumption and the rate of aerobic and anaerobic lactate production by Ehrlich ascites tumor cells has been investigated. The rate of oxygen consumption decreases exponentially with the increase of Lonidamine concentration, with maximal inhibition occurring at 0.40 mM Lonidamine. The rate of aerobic lactate production is inhibited to the same extent as is the oxygen consumption. However, the maximum effect is observed at 0.12 mM Lonidamine, and the decrease is linear with Lonidamine concentration. Anaerobic lactate production is more sensitive to Lonidamine, and complete inhibition can be observed by raising the concentration to 0.6 mM. The possibility that the decrease observed in lactate production was secondary to the inhibition of sodium- and potassium-containing adenosinetriphosphatase was excluded, because the drug has no effect on this enzyme. Mitochondrial adenosinetriphosphatase was not affected. Lonidamine was, however, shown to inhibit the activity of mitochondrially bound hexokinase to approximately the same extent as it inhibited aerobic glycolysis (approximately 70%). It is concluded that inhibition of the glycolysis of Ehrlich ascites tumor cells by Lonidamine results from an effect of the drug on the mitochondrially bound hexokinase.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7306982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Individuation of subcellular targets of antitumor agents by ultrastructural methods.

Authors:  G Arancia
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

Review 2.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Authors:  Lara Milane; Shanthi Ganesh; Shruti Shah; Zhen-Feng Duan; Mansoor Amiji
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

Review 3.  Small mitochondria-targeting molecules as anti-cancer agents.

Authors:  Feng Wang; Marcia A Ogasawara; Peng Huang
Journal:  Mol Aspects Med       Date:  2009-12-06

4.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Kinetic and survival response of the M14 cell line to lonidamine associated with adriamycin or hyperthermia.

Authors:  G Starace; G Badaracco; A Bertuzzi; A Gandolfi; C Greco; M D Totaro; R Vitelli; G Zupi
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.

Authors:  Vera Miranda-Gonçalves; Mrinalini Honavar; Céline Pinheiro; Olga Martinho; Manuel M Pires; Célia Pinheiro; Michelle Cordeiro; Gil Bebiano; Paulo Costa; Isabel Palmeirim; Rui M Reis; Fátima Baltazar
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

7.  The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.

Authors:  C M Carapella; M G Paggi; F Cattani; G B Ciottoli; A Floridi; B Iandolo; L Raus; A Riccio; A Caputo
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

Review 8.  Mechanism of antineoplastic activity of lonidamine.

Authors:  Kavindra Nath; Lili Guo; Bethany Nancolas; David S Nelson; Alexander A Shestov; Seung-Cheol Lee; Jeffrey Roman; Rong Zhou; Dennis B Leeper; Andrew P Halestrap; Ian A Blair; Jerry D Glickson
Journal:  Biochim Biophys Acta       Date:  2016-08-04

9.  (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.

Authors:  Kavindra Nath; David S Nelson; Andrew M Ho; Seung-Cheol Lee; Moses M Darpolor; Stephen Pickup; Rong Zhou; Daniel F Heitjan; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2012-06-29       Impact factor: 4.044

10.  Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.

Authors:  B A Teicher; T S Herman; J Tanaka; B Dezube; A Pardee; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.